NN6 Stock Overview
Develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
NanoRepro AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.33 |
| 52 Week High | €2.25 |
| 52 Week Low | €1.27 |
| Beta | -2.99 |
| 1 Month Change | -14.47% |
| 3 Month Change | -26.32% |
| 1 Year Change | -35.75% |
| 3 Year Change | -80.24% |
| 5 Year Change | 83.45% |
| Change since IPO | -89.10% |
Recent News & Updates
Recent updates
Cautious Investors Not Rewarding NanoRepro AG's (ETR:NN6) Performance Completely
Mar 01
The Market Lifts NanoRepro AG (ETR:NN6) Shares 28% But It Can Do More
Sep 13A Look At The Intrinsic Value Of NanoRepro AG (ETR:NN6)
Aug 04NanoRepro (ETR:NN6) Is Experiencing Growth In Returns On Capital
Apr 12NanoRepro (ETR:NN6) Is Doing The Right Things To Multiply Its Share Price
Dec 15Robust Earnings May Not Tell The Whole Story For NanoRepro (ETR:NN6)
May 29NanoRepro AG's (ETR:NN6) Stock Is Going Strong: Have Financials A Role To Play?
Jan 04Shareholder Returns
| NN6 | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | -6.3% | -2.9% | -2.6% |
| 1Y | -35.7% | -8.5% | 6.9% |
Return vs Industry: NN6 underperformed the German Medical Equipment industry which returned -8.5% over the past year.
Return vs Market: NN6 underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| NN6 volatility | |
|---|---|
| NN6 Average Weekly Movement | 5.9% |
| Medical Equipment Industry Average Movement | 6.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: NN6 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: NN6's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 22 | Lisa Jungst | www.nanorepro.com |
NanoRepro AG develops, manufactures, and distributes rapid diagnostic tests and food supplements for home and professional use in Germany and internationally. It provides products in the areas of family planning and disease detection, as well as food intolerances, allergies, and infectious diseases. The company offers rapid diagnostic tests, such as family planning, and preventive healthcare line products; tests for hospitals and medical practices to detect aids, Troponin I, D-dimer, streptococci antigen, influenza type A and B antigens, and microalbumin; and immunochromatographic lateral flow tests for the diagnostic detection of biomarkers, as well as SARS-CoV-2 antibody test and corona antigen rapid test.
NanoRepro AG Fundamentals Summary
| NN6 fundamental statistics | |
|---|---|
| Market cap | €16.78m |
| Earnings (TTM) | -€3.20m |
| Revenue (TTM) | €3.56m |
4.7x
P/S Ratio-5.2x
P/E RatioIs NN6 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NN6 income statement (TTM) | |
|---|---|
| Revenue | €3.56m |
| Cost of Revenue | €1.21m |
| Gross Profit | €2.35m |
| Other Expenses | €5.55m |
| Earnings | -€3.20m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.25 |
| Gross Margin | 66.07% |
| Net Profit Margin | -89.81% |
| Debt/Equity Ratio | 0% |
How did NN6 perform over the long term?
See historical performance and comparisonDividends
11.3%
Current Dividend Yield-34%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 06:19 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
NanoRepro AG is covered by 4 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Norbert Kalliwoda | Dr. Kalliwoda Research |
| Edward Acklin | First Berlin Equity Research GmbH |
| Cosmin Filker | GBC AG |